DOP2015000259A - Derivados de espiroindolina como antagonistas del receptor de la hormona liberadora de gonadotropina - Google Patents

Derivados de espiroindolina como antagonistas del receptor de la hormona liberadora de gonadotropina

Info

Publication number
DOP2015000259A
DOP2015000259A DO2015000259A DO2015000259A DOP2015000259A DO P2015000259 A DOP2015000259 A DO P2015000259A DO 2015000259 A DO2015000259 A DO 2015000259A DO 2015000259 A DO2015000259 A DO 2015000259A DO P2015000259 A DOP2015000259 A DO P2015000259A
Authority
DO
Dominican Republic
Prior art keywords
bodies
pestrial
spiroindoline
derivatives
diseases
Prior art date
Application number
DO2015000259A
Other languages
English (en)
Inventor
Gernot Langer
Reinhard Nubbemeyer
Stefan BÄURLE
Katrin Nowak-Reppel
Olaf Panknin
Sven Ring
Andrea Wagenfeld
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48047908&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2015000259(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of DOP2015000259A publication Critical patent/DOP2015000259A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

DERIVADOS DE ESPIROINDOLINA, PROCESOS PARA SU PREPARACIÓN Y COMPOSICIONES FARMACÉUTICAS CON LOS MISMOS, SU USO PARA EL TRATAMIENTO DE ENFERMEDADES Y SU USO EN LA ELABORACIÓN DE MEDICAMENTOS PARA EL TRATAMIENTO DE ENFERMEDADES, EN ESPECIAL ENFERMEDADES RELACIONADAS CON LAS HORMONAS SEXUALES, TANTO EN HOMBRES COMO EN MUJERES, EN PARTICULAR AQUELLAS SELECCIONADAS DEL GRUPO DE ENDOMETRIOSIS, LEIOMIOMA UTERINO (FIBROIDES), ENFERMEDAD DE OVARIO POLIQUÍSTICO, MENORRAGIA, DISMENORREA, HIRSUTISMO, PUBERTAD PRECOZ, NEOPLASIAS DEPENDIENTES DE ESTEROIDES GONADALES TALES COMO CÁNCERES DE PRÓSTATA, DE MAMA Y DE OVARIO, ADENOMAS PITUITARIOS GONADOTRÓPICOS, APNEA DEL SUEÑO, SÍNDROME DE INTESTINO IRRITABLE, SÍNDROME PREMENSTRUAL, HIPERTROFIA PROSTÁTICA BENIGNA, ANTICONCEPCIÓN, ESTERILIDAD Y TERAPIA DE REPRODUCCIÓN ASISTIDA TAL COMO LA FERTILIZACIÓN IN VITRO. LA PRESENTE SOLICITUD SE RELACIONA EN PARTICULAR CON DERIVADOS DE ESPIROINDOLINA COMO ANTAGONISTAS DEL RECEPTOR DE LA HORMONA LIBERADORA DE GONADOTROPINA (GNRH).
DO2015000259A 2013-04-09 2015-10-09 Derivados de espiroindolina como antagonistas del receptor de la hormona liberadora de gonadotropina DOP2015000259A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13162986 2013-04-09

Publications (1)

Publication Number Publication Date
DOP2015000259A true DOP2015000259A (es) 2015-11-15

Family

ID=48047908

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2015000259A DOP2015000259A (es) 2013-04-09 2015-10-09 Derivados de espiroindolina como antagonistas del receptor de la hormona liberadora de gonadotropina

Country Status (28)

Country Link
US (1) US20160052936A1 (es)
EP (1) EP2984092A1 (es)
JP (1) JP2016519104A (es)
KR (1) KR20150139917A (es)
CN (1) CN105308053A (es)
AP (1) AP2015008822A0 (es)
AR (1) AR095785A1 (es)
AU (1) AU2014253232A1 (es)
BR (1) BR112015025700A2 (es)
CA (1) CA2908869A1 (es)
CL (1) CL2015003013A1 (es)
CR (1) CR20150530A (es)
CU (1) CU20150141A7 (es)
DO (1) DOP2015000259A (es)
EA (1) EA201501000A1 (es)
HK (1) HK1216101A1 (es)
IL (1) IL241067A0 (es)
MA (1) MA38463B1 (es)
MX (1) MX2015014267A (es)
NI (1) NI201500149A (es)
PE (1) PE20160007A1 (es)
PH (1) PH12015502318A1 (es)
SG (1) SG11201506962TA (es)
TN (1) TN2015000453A1 (es)
TW (1) TW201518304A (es)
UY (1) UY35526A (es)
WO (1) WO2014166958A1 (es)
ZA (1) ZA201508209B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201992612A1 (ru) 2017-06-05 2020-05-20 Обсева С.А. Схемы применения антагониста гонадотропин-высвобождающего гормона для лечения эндометриоза

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0213715D0 (en) * 2002-06-14 2002-07-24 Syngenta Ltd Chemical compounds
WO2013107743A1 (en) * 2012-01-16 2013-07-25 Bayer Intellectual Property Gmbh Spiroindoline derivatives as gonadotropin- releasing hormone receptor antagonists

Also Published As

Publication number Publication date
CR20150530A (es) 2016-01-29
WO2014166958A1 (en) 2014-10-16
MX2015014267A (es) 2016-03-01
TN2015000453A1 (en) 2017-04-06
AU2014253232A1 (en) 2015-11-05
UY35526A (es) 2014-11-28
CL2015003013A1 (es) 2016-04-08
IL241067A0 (en) 2015-11-30
HK1216101A1 (zh) 2016-10-14
NI201500149A (es) 2015-11-30
MA38463A1 (fr) 2018-05-31
EA201501000A1 (ru) 2016-04-29
ZA201508209B (en) 2018-05-30
CU20150141A7 (es) 2016-03-31
CA2908869A1 (en) 2014-10-16
MA38463B1 (fr) 2018-11-30
KR20150139917A (ko) 2015-12-14
EP2984092A1 (en) 2016-02-17
PE20160007A1 (es) 2016-02-14
AR095785A1 (es) 2015-11-11
AP2015008822A0 (en) 2015-10-31
BR112015025700A2 (pt) 2017-07-18
CN105308053A (zh) 2016-02-03
PH12015502318A1 (en) 2016-02-15
TW201518304A (zh) 2015-05-16
SG11201506962TA (en) 2015-10-29
US20160052936A1 (en) 2016-02-25
JP2016519104A (ja) 2016-06-30

Similar Documents

Publication Publication Date Title
DOP2015000202A (es) Derivados de benzotiofeno y composiciones de los mismos como degradantes selectivos de los receptores de estrógeno
SV2017005487A (es) Derivados de 4h-pirrol[3,2-c]piridin-4-ona
NI201500093A (es) Modulador del receptor de andrógenos y usos de este
GT201500138A (es) Novedososo derivados de bencimidazol como antagonistas de ep4
PH12016500953A1 (en) Tricyclic compounds as anticancer agents
CU20140088A7 (es) Derivados de espiroindolina como antagonistas del receptor de la hormona liberadora de gonadotropina
PE20151436A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
CL2014001853A1 (es) Compuestos derivados de pirrol sustituido; procedimiento de preparacion; composicion farmaceutica que los contiene; combinacion farmaceutica; uso para tratar enfermedades tales como canceres y enfermedades del sistema inmunitario.
EA201691808A8 (ru) Кортикостероидные композиции для местного применения
CL2015002202A1 (es) Benzamidas sustituidas con actividad hacia receptores ep4.
BR112015030387A8 (pt) compostos de pirazol moduladores de fshr, seu processo de fabricação, composição farmacêutica que os compreende, bem como uso dos mesmos
CL2016000063A1 (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen.
ECSP16012582A (es) Compuestos heterocíclicos y métodos de uso
UY35906A (es) Novedosos derivados de bencimidazol como ligandos de ep4
CR20140257A (es) Nuevos 2h-indazoles como antagonistas del receptor ep2
PH12016500978A1 (en) Piperazine derivatives having multimodal activity against pain
MX364985B (es) Antagonistas de imidazolil progesterona.
CL2020001075A1 (es) Amidas de imidazopiridina sustituidas y su uso
UY35922A (es) Derivados de sulfonamidas tricíclicas
BR112016001106A8 (pt) Derivados de espiro [2,4] heptano interligados piperazina substituídos como agonistas do receptor de alx
DOP2015000259A (es) Derivados de espiroindolina como antagonistas del receptor de la hormona liberadora de gonadotropina
MX2016002502A (es) Composiciones farmaceuticas de bendamustina.
UY35662A (es) Derivados de espiroindolina y composiciones farmacéuticas de los mismos
BR112014019351A8 (pt) Análogos de tiazolidinona deuterados como agonistas para o receptor do hormônio folículo estimulante